CNS Pharmacology: Drugs for Alzheimer’s Disease

Introduction/Overview

Alzheimer’s disease (AD) represents the most common form of dementia, characterized by progressive cognitive decline and neuropsychiatric disturbances. The pathophysiological cascade involves amyloid‑β (Aβ) aggregation, tau hyperphosphorylation, cholinergic deficits, excitotoxicity, and neuroinflammation. Pharmacologic interventions aim to ameliorate symptoms, modify disease trajectory, or target underlying pathology. In clinical practice, cholinesterase inhibitors and NMDA receptor antagonists constitute the mainstay of symptomatic therapy, whereas monoclonal antibodies directed against Aβ and investigational agents targeting tau are gradually entering therapeutic paradigms. Understanding pharmacodynamics, pharmacokinetics, therapeutic profiles, and safety considerations is essential for optimizing patient outcomes and mitigating adverse events.

Learning objectives:

• Describe the pharmacologic classes employed in AD management and their clinical rationales.
• Explain the molecular mechanisms underlying cholinesterase inhibition, NMDA antagonism, and anti‑amyloid immunotherapy.
• Summarize absorption, distribution, metabolism, and excretion characteristics of key AD drugs.
• Identify major adverse effects and drug‑drug interactions pertinent to AD pharmacotherapy.
• Apply special population considerations to dosing and safety decisions in AD patients.

Classification

Symptomatic Agents

• Cholinesterase Inhibitors (ChEIs) – donepezil, rivastigmine, galantamine.
• NMDA Receptor Antagonist – memantine.

Disease‑Modifying Therapies

• Aβ‑Targeting Monoclonal Antibodies – aducanumab, lecanemab, donanemab, gantenerumab, solanezumab.
• Tau‑Targeting Agents – non‑clinical, investigational compounds such as LMTX, ABBV‑340, and others.
• Small‑Molecule Modulators – beta‑secretase (BACE) inhibitors, gamma‑secretase modulators, and anti‑inflammatory agents under investigation.

Adjunctive and Off‑Label Medications

• Antidepressants (SSRIs, SNRIs) for behavioral disturbances.
• Antipsychotics (haloperidol, atypical agents) for agitation or psychosis.
• Antiepileptics (levetiracetam) for seizures or behavioral symptoms.

Mechanism of Action

Cholinesterase Inhibitors

These agents competitively inhibit acetylcholinesterase (AChE), thereby increasing synaptic acetylcholine (ACh) concentration. Enhanced cholinergic neurotransmission improves attention, memory encoding, and executive function. Galantamine also binds to nicotinic acetylcholine receptors (nAChRs), potentiating receptor sensitivity. The net effect is a modest, yet clinically observable, reduction in cognitive decline over 6–12 months.

NMDA Receptor Antagonist – Memantine

Memantine functions as a low‑affinity, voltage‑dependent NMDA receptor antagonist. It preferentially blocks pathological, excessive glutamatergic activity while preserving normal synaptic transmission. By preventing excitotoxic calcium influx, memantine attenuates neuronal loss and may stabilize disease progression, particularly in moderate to severe AD.

Anti‑Amyloid β Monoclonal Antibodies

These biologics bind extracellular or intracellular Aβ species, promoting clearance via microglial phagocytosis or inhibiting aggregation. The antibodies target specific epitopes: aducanumab and lecanemab recognize aggregated fibrillar Aβ; solanezumab binds soluble Aβ monomers. By reducing amyloid plaque burden, these agents aim to slow cognitive deterioration. The precise mechanism of cognition improvement remains under investigation, with hypotheses involving reduction of neuroinflammation, restoration of synaptic integrity, and modulation of tau pathology.

Tau‑Targeting Strategies

Current tau therapeutics include microtubule stabilizers, kinase inhibitors, immunotherapies, and aggregation blockers. By preventing tau hyperphosphorylation or promoting clearance of neurofibrillary tangles, these agents may address a key driver of neuronal dysfunction. However, clinical efficacy has yet to be demonstrated.

Pharmacokinetics

Donepezil

Donepezil is orally absorbed, with peak plasma concentrations at 2–4 h. It is highly lipophilic, enabling central nervous system penetration. Distribution volume approximates 3 L/kg, and protein binding is 86 %. Metabolism is primarily hepatic via CYP3A4 and CYP2D6, yielding inactive metabolites. Renal excretion accounts for 20 % of the dose. The terminal half‑life (t_1/2) is 70 h, allowing once‑daily dosing. Dose adjustment is not routinely required for mild to moderate renal impairment; however, caution is advised in severe impairment.

Rivastigmine

Rivastigmine is available as oral or transdermal formulations. Oral absorption peaks at 2 h, whereas transdermal levels rise steadily, achieving steady state after 4–7 days. Its bioavailability is 10–30 % due to first‑pass metabolism. Rivastigmine is metabolized by hydrolysis and glucuronidation, with negligible CYP involvement. The half‑life is 1–2 h for oral, but transdermal delivery maintains therapeutic levels over 24 h, permitting once‑daily dosing. Renal or hepatic impairment does not necessitate dose modification.

Galantamine

Galantamine achieves peak plasma levels within 1–3 h post‑dose. It undergoes hepatic metabolism via CYP2D6, CYP3A4, and CYP1A2, resulting in active metabolites. The t_1/2 is 7–8 h, supporting twice‑daily dosing. Dose adjustments are recommended in severe hepatic impairment and for concomitant CYP2D6 inhibitors.

Memantine

Memantine displays rapid absorption, with peak concentrations at 1–2 h. It is largely distributed in the central nervous system, with a volume of distribution of 0.6 L/kg. Metabolism is minimal; the drug is primarily renally eliminated unchanged. The t_1/2 is 60–80 h, allowing once‑daily dosing. Renal impairment necessitates dose reduction proportional to creatinine clearance.

Monoclonal Antibodies (Aducanumab, Lecanemab, Donanemab)

These biologics are administered intravenously, with peak serum concentrations achieved immediately post‑infusion. Distribution is largely confined to plasma and interstitial fluid, with limited blood–brain barrier penetration. Metabolism follows the proteolytic degradation pathway of endogenous immunoglobulins. Clearance is driven by target‑mediated and non‑target‑mediated pathways. Half‑life ranges from 12 to 21 days, permitting dosing intervals of 2–4 weeks. Renal and hepatic functions exert minimal influence on pharmacokinetics. However, infusion reactions and amyloid‑related imaging abnormalities (ARIA) require careful monitoring.

Therapeutic Uses/Clinical Applications

Symptomatic Management

• Cholinesterase inhibitors are indicated for mild, moderate, and severe AD, with evidence of modest cognitive and functional benefits.
• Memantine is approved for moderate to severe AD, particularly when combined with a ChEI.

Disease‑Modifying Therapy

• Aducanumab, lecanemab, and donanemab are indicated for early AD (mild cognitive impairment or mild AD) with biomarker confirmation of amyloid pathology. Monitoring for ARIA and adherence to infusion protocols are essential.
• Investigational tau‑targeting agents are pending regulatory approval; clinical trials evaluate efficacy in slowing cognitive decline across disease stages.

Off‑Label and Adjunctive Uses

• ChEIs and memantine are occasionally prescribed for vascular dementia, Lewy body dementia, and Parkinson’s disease dementia, although evidence is less robust.
• Antidepressants and antipsychotics are employed for behavioral and psychological symptoms of dementia (BPSD), with caution due to heightened sensitivity to adverse events.

Adverse Effects

Cholinesterase Inhibitors

• Gastro‑intestinal: nausea, vomiting, diarrhea, anorexia, and weight loss.
• Cardiac: bradycardia, sinus pauses, and heart block, particularly in patients with pre‑existing conduction abnormalities.
• Central: insomnia, vivid dreams, agitation, and, rarely, seizures.
• Rivastigmine transdermal: skin irritation at the application site.

Memantine

• Central nervous system: headache, dizziness, confusion, hallucinations, and, in rare cases, seizures.
• Non‑specific: constipation, fatigue.

Monoclonal Antibodies

• Infusion‑related reactions: fever, chills, hypotension, and rash, occurring primarily during the first infusion.
• Amyloid‑related imaging abnormalities (ARIA‑E and ARIA‑H) manifest as cerebral edema or microhemorrhages; risk increases with APOE ε4 genotype.
• Infections: increased rates of upper respiratory tract infections and, potentially, opportunistic infections due to immune modulation.

Other Antipsychotic/Antidepressant Adverse Effects

• Haloperidol: extrapyramidal symptoms, tardive dyskinesia, neuroleptic malignant syndrome.
• Atypical antipsychotics: metabolic syndrome, orthostatic hypotension, QT prolongation.
• SSRIs/SNRIs: serotonin syndrome, hyponatremia, bleeding diathesis.

Drug Interactions

Cholinesterase Inhibitors

• Anticholinergic agents (e.g., diphenhydramine, tricyclic antidepressants) diminish therapeutic benefit.
• MAO‑I inhibitors may precipitate severe anticholinergic toxicity.
• Antiplatelet agents increase risk of GI bleeding.
• Beta‑blockers and calcium channel blockers may exacerbate bradycardia.

Memantine

• Concurrent use with other NMDA antagonists (e.g., ketamine, dextromethorphan) may potentiate CNS depression.
• Central nervous system depressants (benzodiazepines, opioids) increase risk of sedation and respiratory depression.

Monoclonal Antibodies

• Concurrent use of antithrombotic therapy (warfarin, DOACs) may elevate bleeding risk during infusion.
• Immunosuppressants (cyclosporine, tacrolimus) could alter antibody clearance, though data are limited.
• Agents causing neutropenia may compound infection risk.

Special Considerations

Pregnancy and Lactation

• ChEIs are classified as pregnancy category C; limited data suggest potential fetal exposure and unknown teratogenicity. Use is generally contraindicated unless benefits outweigh risks.
• Memantine has insufficient safety data; it is typically avoided during pregnancy and lactation.
• Monoclonal antibodies have not been studied in pregnancy; theoretical placental transfer raises concerns.

Pediatric Considerations

AD is exceedingly rare in children; therapeutic indications are limited. Off‑label use of ChEIs or memantine is discouraged without robust evidence. Clinical trials are ongoing for early-onset AD related to genetic mutations.

Geriatric Considerations

• Age‑related pharmacokinetic changes necessitate careful dosing, particularly for drugs with renal excretion (memantine). Dose titration should commence at the lowest effective dose.
• Polypharmacy increases interaction risk; comprehensive medication review is advisable.
• Monitoring for falls, orthostatic hypotension, and cognitive over‑medication is critical.

Renal and Hepatic Impairment

• Donepezil: no dose adjustment for mild‑moderate renal impairment; severe impairment requires caution.
• Memantine: dose reduction proportional to creatinine clearance; e.g., 5 mg daily for <30 mL/min.
• Galantamine: dose reduction or avoidance in severe hepatic impairment.
• Rivastigmine: no adjustment needed; transdermal route bypasses hepatic metabolism.
• Monoclonal antibodies: no adjustment; however, monitoring for ARIA is essential regardless of organ function.

Summary/Key Points

• Symptomatic therapy relies on cholinesterase inhibitors and memantine, each with distinct mechanisms and side‑effect profiles.
• The advent of anti‑Aβ monoclonal antibodies represents a shift toward disease‑modifying care, contingent upon biomarker confirmation and rigorous monitoring.
• Pharmacokinetic properties guide dosing schedules: long half‑lives of ChEIs permit once‑daily regimens, whereas memantine requires careful titration in renal impairment.
• Adverse events range from mild gastrointestinal disturbances to serious infusion reactions and ARIA; patient selection and monitoring are paramount.
• Polypharmacy, geriatric physiology, and organ dysfunction necessitate individualized treatment plans and vigilant surveillance for drug interactions.

References

1. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
2. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
3. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
4. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
5. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
6. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
7. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
8. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.